Table of Contents
Chemotherapy Research and Practice
Volume 2014, Article ID 856156, 4 pages
http://dx.doi.org/10.1155/2014/856156
Research Article

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients

1Department of Medical Oncology, Tata Memorial Hospital, Dr. E. Borges Road, Parel, Mumbai, Maharashtra 400012, India
2Department of Medical Oncology, Malabar Cancer Center, Moozhikkara, Kannur, Kerala 670103, India
3Department of Radiodiagnosis, Tata Memorial Hospital, Dr. E. Borges Road, Parel, Mumbai, Maharashtra 400012, India
4Department of Nuclear Medicine, Tata Memorial Hospital, Dr. E. Borges Road, Parel, Mumbai, Maharashtra 400012, India
5Department of Pathology, Tata Memorial Hospital, Dr. E. Borges Road, Parel, Mumbai, Maharashtra 400012, India

Received 26 September 2014; Accepted 17 November 2014; Published 7 December 2014

Academic Editor: Vassilis Georgoulias

Copyright © 2014 Vanita Noronha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. B. Sorensen, H. H. Hansen, M. Hansen, and P. Dombernowsky, “Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis,” Journal of Clinical Oncology, vol. 6, no. 9, pp. 1474–1480, 1988. View at Google Scholar · View at Scopus
  2. M. A. Chidel, J. H. Suh, J. F. Greskovich, P. A. Kupelian, and G. H. Barnett, “Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis,” Radiation Oncology Investigations, vol. 7, no. 5, pp. 313–319, 1999. View at Google Scholar
  3. E. C. A. Kaal, C. G. J. H. Niël, and C. J. Vecht, “Therapeutic management of brain metastasis,” The Lancet Neurology, vol. 4, no. 5, pp. 289–298, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Porta, J. M. Sánchez-Torres, L. Paz-Ares et al., “Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation,” European Respiratory Journal, vol. 37, no. 3, pp. 624–631, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. V. R. Bhatt, S. Kedia, A. Kessinger, and A. K. Ganti, “Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations,” Journal of Clinical Oncology, vol. 31, no. 25, pp. 3162–3164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Chougule, K. Prabhash, V. Noronha et al., “Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity,” PLoS ONE, vol. 8, no. 10, Article ID e76164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. C. H. Gow, C. R. Chien, Y. L. Chang et al., “Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response,” Clinical Cancer Research, vol. 14, no. 1, pp. 162–168, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Cappuzzo, A. Ardizzoni, H. Soto-Parra et al., “Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC),” Lung Cancer, vol. 41, no. 2, pp. 227–231, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. F. A. Shepherd, J. R. Pereira, T. Ciuleanu et al., “Erlotinib in previously treated non-small-cell lung cancer,” The New England Journal of Medicine, vol. 353, no. 2, pp. 123–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. Lee, I. Khan, S. Upadhyay et al., “First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial,” The Lancet Oncology, vol. 13, no. 11, pp. 1161–1170, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. P. A. Jänne, X. Wang, M. A. Socinski et al., “Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial,” Journal of Clinical Oncology, vol. 30, no. 17, pp. 2063–2069, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. D.-Y. Kim, K.-W. Lee, T. Yun et al., “Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer,” Oncology Reports, vol. 14, no. 1, pp. 207–211, 2005. View at Google Scholar · View at Scopus
  13. A. F. Eichler, K. T. Kahle, D. L. Wang et al., “EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer,” Neuro-Oncology, vol. 12, no. 11, pp. 1193–1199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Hotta, K. Kiura, H. Ueoka et al., “Effect of gefitinib (“Iressa”, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer,” Lung Cancer, vol. 46, no. 2, pp. 255–261, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J.-E. Kim, D. H. Lee, Y. Choi et al., “Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis,” Lung Cancer, vol. 65, no. 3, pp. 351–354, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Asahina, K. Yamazaki, I. Kinoshita et al., “A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations,” British Journal of Cancer, vol. 95, no. 8, pp. 998–1004, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. H. Jung, C. W. Han, Y. D. Jung, Y. Y. Cho, and D. J. Han, “Complete remission of brain metastases in non-small cell lung cancer patients harboring an EGFR mutation treated with tyrosine kinase inhibitor without radiotherapy: a report of 3 cases,” Case Reports in Oncology, vol. 7, no. 1, pp. 149–154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Jamal-Hanjani and J. Spicer, “Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain,” Clinical Cancer Research, vol. 18, no. 4, pp. 938–944, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. H. G. Yi, H. J. Kim, Y. J. Kim et al., “Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI,” Lung Cancer, vol. 65, no. 1, pp. 80–84, 2009. View at Publisher · View at Google Scholar · View at Scopus